Get the Stockscreener App
17.68
1.12%
-0.20
After Hours:
17.68
Ars Pharmaceuticals Inc stock is traded at $17.68, with a volume of 1.09M.
It is down -1.12% in the last 24 hours and up +1.32% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$17.88
Open:
$17.75
24h Volume:
1.09M
Relative Volume:
0.79
Market Cap:
$1.74B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-37.62
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-1.34%
1M Performance:
+1.32%
6M Performance:
+35.79%
1Y Performance:
+62.65%
1-Day Range:
$17.51
$17.91
1-Week Range:
$17.41
$18.63
52-Week Range:
$8.9055
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
17.68 | 1.76B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Why is ARS Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Picks With High Returns - jammulinksnews.com
What institutional investors are buying ARS Pharmaceuticals Inc. stockReal Time Tracker With High Returns - jammulinksnews.com
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength - Yahoo Finance
What is the risk reward ratio of investing in ARS Pharmaceuticals Inc. stockBeginner Investor Strategy With Proven Results - jammulinksnews.com
Quant Models Detect Momentum Reversal in ARS Pharmaceuticals Inc.Trend Analysis for Safer Trades Gains Popularity - metal.it
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
ARS Pharmaceuticals Inc.’s Price Action Aligns with Quant SignalsTarget Return Focused Trade Insights Shared - metal.it
What institutions are buying ARS Pharmaceuticals Inc. stock nowReal Time Stock Movement Analysis Indicates Breakout - metal.it
How strong is ARS Pharmaceuticals Inc. company’s balance sheetStay informed with expert market forecasts - jammulinksnews.com
Is ARS Pharmaceuticals Inc. a growth stock or a value stockSuperior risk-adjusted returns - jammulinksnews.com
When is ARS Pharmaceuticals Inc. stock expected to show significant growthProven strategies for superior portfolio growth - jammulinksnews.com
What makes ARS Pharmaceuticals Inc. stock price move sharplyGet timely advice on market trends - jammulinksnews.com
Should I hold or sell ARS Pharmaceuticals Inc. stock in 2025Consistent double returns - jammulinksnews.com
ARS Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - PrintWeekIndia
Is ARS Pharmaceuticals Inc. a good long term investmentTriple-digit return opportunities - PrintWeekIndia
What drives ARS Pharmaceuticals Inc. stock priceTremendous growth opportunities - Autocar Professional
What analysts say about ARS Pharmaceuticals Inc. stockBreakthrough stock performance - jammulinksnews.com
MHRA approves needle-free adrenaline nasal spray for anaphylaxis - Yahoo Finance
EURneffy® (adrenaline nasal spray) Approved in the U.K. as - GlobeNewswire
Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment - Stock Titan
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):